<?xml version="1.0" encoding="UTF-8"?>
<results title="zoonosis">
 <result pre="paid to IFN-I treatment in patients with severe COVID-19. Abstract" exact="Coronavirus disease 2019" post="(COVID-19) first emerged in late 2019 in China. At"/>
 <result pre="Beta Interferon 1 Introduction The rapid and devastating outbreak of" exact="Coronavirus disease 2019" post="(COVID-19) pandemic and the lack of approved treatments for"/>
 <result pre="of the IFN-I system and the dysregulated IFN-I response in" exact="SARS-CoV-2 infection" post="point to the need of a fine-tuning of route,"/>
 <result pre="pathogenic mechanisms intervening in early stage versus late stage of" exact="SARS-CoV-2 infection" post="(reviewed in [17]) and to the role of comorbidities"/>
 <result pre="of disease and fatal outcomes in MERS patients [26]. Likewise," exact="SARS-CoV-2 infection" post="(either in cell lines, primary cell cultures, ferrets, and"/>
 <result pre="results are in line with data on mouse model of" exact="SARS-CoV infection," post="where a robust viral replication associated with delayed IFN-I"/>
 <result pre="disease [32]. In conclusion, in comparison to other respiratory viruses," exact="SARS-CoV-2 infection" post="drives a lower antiviral transcriptional response that is marked"/>
 <result pre="systemic effects potentially protective in the very early phases of" exact="SARS-CoV-2 infection." post="Several clinical trials using inhaled IFN-Î± either as monotherapy"/>
 <result pre="intranasal administration of IFN-Î± to medical staff at risk of" exact="SARS-CoV-2 infection" post="results in complete protection [61]. Since the beneficial effects"/>
 <result pre="stimulus, further studies are needed to confirm IFN-I efficacy against" exact="SARS-CoV-2 infection" post="and to better characterize the biological activities, the mechanisms"/>
 <result pre="urgent need to identify antiviral agents immediately available to combat" exact="SARS-CoV-2 infection." post="As shown in Table 1 , among the many"/>
 <result pre="at least in part, responsible for the spontaneous resolution of" exact="SARS-CoV-2 infection" post="in the majority of infected patients (estimated around 80"/>
 <result pre="role of the endogenous IFN-I signaling in the susceptibility to" exact="SARS-CoV-2 infection" post="and in the progression to the severe forms of"/>
 <result pre="type I interferon activity and exacerbated inflammatory responses in severe" exact="Covid-19" post="patientsMedRxiv.202010.1101/2020.04.19.20068015 28Trouillet-AssantS.VielS.GaymardA.PonsS.RichardJ.-C.PerretM.VillardM.Brengel-PesceK.LinaB.MezidiM.BitkerL.BelotA.MoutonW.OriolG.CompagnonC.GenerenazL.CheynetV.AderF.BeckerA.BenechN.ChauvelotP.ChidiacC.ConradA.FerryT.MiailhesP.PerpointT.PerryM.PouderouxC.RouxS.Triffault-FillitC.ValourF.HodaneY.ChauvelotL.ChabertP.ProvoostJ.DavidG.FollietL.LecamP.BillaudG.BouscambertM.EscuretV.FrobertE.BalA.DestrasG.JossetL.MorfinF.MunierC.ValetteM.VenetF.GarnierL.PescarmonaR.LombardC.WalzerT.Type I IFN immunoprofiling in COVID-19 patientsJ. Allergy"/>
 <result pre="Host Microbe19201618119310.1016/j.chom.2016.01.00726867177 32ChannappanavarR.FehrA.R.ZhengJ.Wohlford-LenaneC.AbrahanteJ.E.MackM.SompallaeR.McCrayP.B.MeyerholzD.K.PerlmanS.IFN-I response timing relative to virus replication determines" exact="MERS coronavirus" post="infection outcomesJ. Clin. Invest.12920193625363910.1172/JCI12636331355779 33Blanco-MeloD.Nilsson-PayantB.E.LiuW.C.UhlS.HoaglandD.MÃ¸llerR.JordanT.X.OishiK.PanisM.SachsD.WangT.T.SchwartzR.E.LimJ.K.AlbrechtR.A.B.R. tenOever, imbalanced host response"/>
 <result pre="49ArabiY.M.AsiriA.Y.AssiriA.M.Aziz JokhdarH.A.AlothmanA.BalkhyH.H.AlJohaniS.Al HarbiS.KojanS.Al JeraisyM.DeebA.M.MemishZ.A.GhazalS.Al FarajS.Al-HameedF.AlSaediA.MandourahY.Al MekhlafiG.A.SherbeeniN.M.ElzeinF.E.AlmotairiA.Al BshabsheA.KharabaA.JoseJ.Al HarthyA.Al SulaimanM.MadyA.FowlerR.A.HaydenF.G.Al-DawoodA.AbdelzaherM.BajhmomW.HusseinM.A.Treatment of" exact="Middle East respiratory syndrome" post="with a combination of lopinavir/ritonavir and interferon-Î²1b (MIRACLE trial):"/>
 <result pre="sequential randomized controlled trialTrials.212020810.1186/s13063-019-3846-x31900204 50OmraniA.S.SaadM.M.BaigK.BahloulA.Abdul-MatinM.AlaidaroosA.Y.AlmakhlafiG.A.AlbarrakM.M.MemishZ.A.AlbarrakA.M.Ribavirin and interferon alfa-2a for severe" exact="Middle East respiratory syndrome" post="coronavirus infection: a retrospective cohort studyLancet Infect. Dis.1420141090109510.1016/S1473-3099(14)70920-X25278221 51ZumlaA.ChanJ.F.W.AzharE.I.HuiD.S.C.YuenK.Y.Coronaviruses-drug"/>
 <result pre="a double-blind, parallel controlled trial during an influenza pandemic year," exact="Influenza" post="Other RespiViruses.7201385486210.1111/irv.12094 60BocciV.Absorption of Cytokines via Oropharyngeal-Associated Lymphoid Tissues:"/>
 <result pre="trial of recombinant human interferon alpha nasal drops to prevent" exact="coronavirus disease 2019" post="in medical staff in an epidemic areaMedRxiv.202010.1101/2020.04.11.200614732020.04.11.20061473 62SallardE.LescureF.-X.YazdanpanahY.MentreF.Peiffer-SmadjaN.Type 1"/>
 <result pre="activities of systemic and mucosal type I Interferons in both" exact="influenza infection" post="as well as tumor models. The research activity is"/>
</results>
